Get started
Cybin, Inc.Cybin, Inc.Cybin, Inc.

Cybin, Inc.

No trades
See on Supercharts
OverviewFinancialsNewsIdeasDiscussionsForecastSeasonalsETFs

R7E chart


Full chart

R7E upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪117.26 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.9720 EUR
Net income (FY)
‪−72.66 M‬ EUR
Revenue (FY)
0.00 EUR
Shares float
‪21.68 M‬
Beta (1Y)
—

Employees


Employees (FY)
50
Revenue / Employee (1Y)
—
Net income / Employee (1Y)
—

About Cybin, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Eric So
Website
cybin.com
Headquarters
Toronto
Founded
2016
ISIN
CA23256X4075
FIGI
BBG00YJ7HKQ8
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Check out other big names from the same industry as R7E.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

R7E news



Ideas



See all ideas 

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on DUS exchange Cybin, Inc. stocks are traded under the ticker R7E.
We've gathered analysts' opinions on Cybin, Inc. future price: according to them, R7E price has a max estimate of 127.80 EUR and a min estimate of 25.47 EUR. Watch R7E chart and read a more detailed Cybin, Inc. stock forecast: see what analysts think of Cybin, Inc. and suggest that you do with its stocks.
R7E reached its all-time high on Nov 18, 2024 with the price of 11.9000 EUR, and its all-time low was 4.3800 EUR and was reached on Apr 9, 2025. View more price dynamics on R7E chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track Cybin, Inc. financials in yearly and quarterly reports right on TradingView.
Cybin, Inc. is going to release the next earnings report on Nov 17, 2025. Keep track of upcoming events with our Earnings Calendar.
R7E earnings for the last quarter are −0.95 EUR per share, whereas the estimation was −0.81 EUR resulting in a −16.34% surprise. The estimated earnings for the next quarter are −0.82 EUR per share. See more details about Cybin, Inc. earnings.
Cybin, Inc. revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
R7E net income for the last quarter is ‪−21.24 M‬ EUR, while the quarter before that showed ‪−19.64 M‬ EUR of net income which accounts for −8.14% change. Track more Cybin, Inc. financial stats to get the full picture.
No, R7E doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 29, 2025, the company has 50 employees. See our rating of the largest employees — is Cybin, Inc. on this list?
Like other stocks, R7E shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cybin, Inc. stock right from TradingView charts — choose your broker and connect to your account.